Recent reports indicate that Bausch Health Cost $BHC, a prominent pharmaceutical company, may soon begin issuing debt securities as part of its strategy to refinance short-term obligations. Sources familiar with the situation have suggested that Bausch Health is considering a deal valued at approximately $5 billion, although specific details and structure are still under discussion.